Most actionable first. Assess the next decision, not the size of the database.
877 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.
WATCH · SUSPENDED
HIV-1-infection
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Temporarily Closed (Paused) to Accrual and Study Agents/Products
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Temporarily Closed (Paused) to Accrual and Study Agents/Products
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-02. Registry source
WATCH · SUSPENDED
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma,...
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Insufficient funding
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Insufficient funding
Why stranded: Financing failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-11. Registry source
WATCH · TERMINATED
Childhood Solid Tumor
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new...
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026).
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-17. Registry source
WATCH · SUSPENDED
Advanced Solid Tumor, Advanced Lymphoma
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule.
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule.
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-01. Registry source
WATCH · TERMINATED
HIV Infections
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT terminated
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
terminated
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2008-01-29. Registry source
WATCH · TERMINATED
Falciparum Malaria
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2006-11-16. Registry source
WATCH · SUSPENDED
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Pending ICF update
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Pending ICF update
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-18. Registry source
WATCH · TERMINATED
Metabolic Diseases, Oxidative Stress
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2006-10-12. Registry source
WATCH · TERMINATED
Chronic Kidney Disease
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2006-10-06. Registry source
WATCH · WITHDRAWN
Chronic Kidney Disease
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Study was terminated due to a lack of foreseeable clinical benefit in the proposed chronic kidney disease population, following the termination of a related heart...
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Study was terminated due to a lack of foreseeable clinical benefit in the proposed chronic kidney disease population, following the termination of a related heart failure study that demonstrated no benefit in an overlapping patient group.
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-08. Registry source
WATCH · TERMINATED
Leukemia, Myelocytic, Acute
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2006-11-14. Registry source
WATCH · TERMINATED
Stroke, Cerebral Infarction, Atherosclerosis, Constriction, Pathologic
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2006-06-06. Registry source